Boswellia serrata Roxb. ex Colebr. · herb
Evidence tier: moderate
Reduces joint inflammation and improves mobility
The boswellic acids, and in particular AKBA (acetyl-11-keto-beta-boswellic acid), are thought to inhibit 5-lipoxygenase, the enzyme that manufactures leukotrienes, a family of inflammatory messengers that drive swelling and pain. This is a different inflammatory pathway from the one that NSAIDs block, which is the usual explanation offered for why boswellia can add something on top of them. This mechanism is well supported in the laboratory. It is a strong hypothesis, not a proven account of what happens in a human knee at the doses people take.
Moderate for knee and joint osteoarthritis, and that is the only use that holds. This is one of the ingredients where honesty runs UPWARD as well as downward: boswellia's osteoarthritis evidence is real, it is randomised, it is consistently positive in direction, and it recently beat its more famous rival. The systematic review and meta analysis by Yu and colleagues (BMC Complementary Medicine and Therapies 2020, PMID 32680575) pooled seven trials in 545 patients and found significant improvements in pain (visual analogue scale and WOMAC pain), in stiffness and in joint function, concluding that 'Boswellia and its extract may be an effective and safe treatment option for patient with OA'. When seven joint supplements were ranked head to head in a 2025 network meta analysis (PMID 40806131), BOSWELLIA, not curcumin, came out on top. The honest brake on all of this is the size of the evidence base, and NCCIH applies it: 'several studies have shown taking boswellia orally may help reduce inflammation and pain associated with osteoarthritis, but LARGER, HIGHER QUALITY STUDIES ARE NEEDED.' Seven trials and 545 patients is a thin foundation for a strong grade, and many of the trials are short and industry linked. That is precisely what a moderate tier is for: real effect, real trials, too small to be certain. Every other indication is weaker or absent. Asthma: NCCIH says 'a few small studies suggest that taking boswellia orally may reduce asthma symptoms. However, there is not enough rigorous evidence to determine whether boswellia is a useful treatment for asthma.' Inflammatory bowel disease: NCCIH does not address it and the seed's claim rests on old, small trials. Rheumatoid arthritis: no adequate evidence. TOPICAL boswellia: NCCIH says there is not sufficient evidence that it works. Safety is the good news, and it is unusually clean for a botanical in this batch: NCCIH states 'boswellia is likely to be safe when taken orally', and there is no LiverTox hepatotoxicity signal of the kind that dominates black cohosh.
NCCIH reports that Boswellia serrata extract at doses of up to 1,000 mg daily has been used safely in several clinical trials lasting up to 6 months, and has also been used with apparent safety at 2,400 mg daily for up to 1 month. Take with food. The 2020 meta analysis found that treatment needs to run for AT LEAST 4 WEEKS before it can be judged.
Daily with food. Effects build over 4 to 6 weeks.
Onset: ~28 days
Generally safe and well tolerated for short to medium term use. Mild GI effects at high doses. Limited human safety data in pregnancy, avoid unless directed by a healthcare provider.
Pregnancy: caution
Breastfeeding: caution
Active compounds: boswellic acids, acetyl-11-keto-beta-boswellic acid (AKBA), beta-boswellic acid
Remedies using Boswellia · Browse by body system · Check it against what you take
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.